Your browser doesn't support javascript.
loading
Comment on 'Baseline use of hydroxychloroquine in systemic lupus erythematosus does not preclude SARS-CoV-2 infection and severe COVID-19' by Konig et al. Long-term exposure to hydroxychloroquine or chloroquine and the risk of hospitalisation with COVID-19: a nationwide, observational cohort study in 54 873 exposed individuals and 155 689 matched unexposed individuals in France.
Sbidian, Emilie; Penso, Laetitia; Herlemont, Philippe; Botton, Jérémie; Baricault, Bérangère; Semenzato, Laura; Drouin, Jérome; Weill, Alain; Dray-Spira, Rosemay; Zureik, Mahmoud.
Afiliación
  • Sbidian E; EPI-PHARE Scientific Interest Group in Epidemiology of Health Products from the French National Agency for the Safety of Medicines and Health Products and the French National Health Insurance, F-93285, Saint Denis, France emilie.sbidian@aphp.fr.
  • Penso L; University Paris-Est Créteil, Research Unit Epidemiology in Dermatology and evaluation of therapeutics, F-94000, Créteil, France.
  • Herlemont P; EPI-PHARE Scientific Interest Group in Epidemiology of Health Products from the French National Agency for the Safety of Medicines and Health Products and the French National Health Insurance, F-93285, Saint Denis, France.
  • Botton J; University Paris-Est Créteil, Research Unit Epidemiology in Dermatology and evaluation of therapeutics, F-94000, Créteil, France.
  • Baricault B; EPI-PHARE Scientific Interest Group in Epidemiology of Health Products from the French National Agency for the Safety of Medicines and Health Products and the French National Health Insurance, F-93285, Saint Denis, France.
  • Semenzato L; EPI-PHARE Scientific Interest Group in Epidemiology of Health Products from the French National Agency for the Safety of Medicines and Health Products and the French National Health Insurance, F-93285, Saint Denis, France.
  • Drouin J; EPI-PHARE Scientific Interest Group in Epidemiology of Health Products from the French National Agency for the Safety of Medicines and Health Products and the French National Health Insurance, F-93285, Saint Denis, France.
  • Weill A; EPI-PHARE Scientific Interest Group in Epidemiology of Health Products from the French National Agency for the Safety of Medicines and Health Products and the French National Health Insurance, F-93285, Saint Denis, France.
  • Dray-Spira R; EPI-PHARE Scientific Interest Group in Epidemiology of Health Products from the French National Agency for the Safety of Medicines and Health Products and the French National Health Insurance, F-93285, Saint Denis, France.
  • Zureik M; EPI-PHARE Scientific Interest Group in Epidemiology of Health Products from the French National Agency for the Safety of Medicines and Health Products and the French National Health Insurance, F-93285, Saint Denis, France.
Ann Rheum Dis ; 82(5): e117, 2023 05.
Article en En | MEDLINE | ID: mdl-32859610
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: COVID-19 / Lupus Eritematoso Sistémico Tipo de estudio: Etiology_studies / Observational_studies / Risk_factors_studies País/Región como asunto: Europa Idioma: En Revista: Ann Rheum Dis Año: 2023 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: COVID-19 / Lupus Eritematoso Sistémico Tipo de estudio: Etiology_studies / Observational_studies / Risk_factors_studies País/Región como asunto: Europa Idioma: En Revista: Ann Rheum Dis Año: 2023 Tipo del documento: Article